Vita Life Sciences Limited
ACN 003 190 421
ABN 35 003 190 421
Corporate Office
Suite 802, Level 8,
1-5 Chalmers Crescent
Mascot NSW 2020
Australia
T: 61 2 9545 2633
F: 61 2 9545 1311
vitalifesciences.com

28 May 2026

Market Announcements
Australian Securities Exchange Ltd
Level 27, 39 Martin Place,
Sydney, NSW 2000

Dear Sir/ Madam,

2026 ANNUAL GENERAL MEETING (AGM)-ADDRESS & PRESENTATION

The Vita Life Sciences Ltd addresses to the 2026 AGM by the Chairman and the Managing Director, with related presentation is attached.

This announcement has been authorised for release by the Board.

Yours faithfully,

Chin L Khoo
Company Secretary
Email: enquiries@vitalifesciences.com.au

Vita Life Sciences Limited – 2026 Annual General Meeting

Chairman's Script - 28 May 2026

Welcome

Good afternoon ladies and gentlemen. I'm Henry Townsing, the Chairman of Vita Life Sciences Limited and the Chairman for the Annual General Meeting today.

Welcome to the VLS 2026 Annual General Meeting.

We are conducting this AGM physically in our office, whereby shareholders may attend in person or observe only, via webinar facility managed by Automic. If you experience any difficulties with your connection to the AGM, you may contact our share registry, Automic on 1300 288 664.

It is now just after 12 pm and, there being a quorum present, I declare the meeting has been properly constituted and open for business.

Introduction

I have pleasure in introducing my fellow Directors who are in attendance:

- Andrew O'Keefe, our Managing Director;
- Jack Teoh, a non-executive Director; and
- Peter Osborne, a non-executive director.

Also present is our Company Secretary and CFO, Mr Chin Khoo and the Company's external auditor representative, Mr Stephen Fisher the audit partner from Nexia. There will be opportunity for shareholders to ask questions to the Auditor as well as the Board on financial and business matters later in the meeting.

OUTLINE OF MEETING

Our business begins with the Managing Director's presentation and, then the formal items of business as set out in the Notice of Meeting.

I would like to welcome those shareholders that are observing us online and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your screen. When you submit a question or comment, please start by typing which resolution it relates to so that it can be addressed at the appropriate time.

Questions which relate to the general business of the Company will be collected and addressed after the close of the formal business of the meeting.

I will now hand over the meeting to Andrew O'Keefe, our Managing Director who will be presenting a report on the Company's business.

Andrew O'Keefe

Thank you, Henry for the introduction.

AGENDA 1 MANAGING DIRECTORS PRESENTATION

Refer to Managing Directors Presentation

[Upon Completion of MD's Presentation Andrew, hands the conduct of the meeting to the Chairman]

AGENDA 2 RESOLUTIONS

Thank you, Andrew for that presentation. We shall now commence the formal business of the meeting.

The Notice of Annual General Meeting was announced to all members and the ASX on 28 April 2026 and is to be taken as read. Voting on all resolutions, will be conducted by poll.

For the purposes of the poll, I appoint the representative of Automic, the Company's share registry, who has examined and prepared summaries of the proxy forms received, to act as Returning Officer and to conduct the poll.

Shareholders observing online who have **already submitted their votes by proxy** should note that your votes will already be counted towards the poll.

The proxies have been inspected and all those validly lodged have been accepted.

Proxies have been received representing up to 36,611,514 Shares or around 67% of the issued capital of the Company.

All undirected proxies or open votes that have nominated the Chairman of the Meeting as their proxy, will be cast in favour of each resolution.

We will now proceed to the resolutions set out in the Notice of AGM.

<u>Financial Statements and Reports of Directors and Auditors</u>

I turn now to the first item of business on the agenda, the consideration of the Financial Statements and Reports. The financial report and the reports of the directors and the auditors are now laid before the meeting. There will be no vote on this item as it is a discussion item only.

The Company's auditor for the 2025 financial year, **Mr Stephen Fisher** of Nexia Sydney Audit Pty Ltd is available to take questions relevant to the conduct of the audit and the preparation and content of the independent auditor's report.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

Is there any discussion or questions on the 2025 Financial Reports?

Are there any questions relevant to the conduct of the audit and the preparation and content of the auditor's report to be put to the auditor?

[PAUSE AND TAKE QUESTIONS]

If there are no further question, I declare that the reports have been received and considered at this meeting.

Remuneration Report

In accordance with the Notice of Meeting, I now move onto item 2, Resolution 1 which is as follows:

To consider and, if thought fit, to pass, with or without amendment, ***Resolution 1****, Adoption of the Remuneration Report for the Financial year ended 31 December 2025, as an* ***ordinary resolution****.*

I note that while the vote on this item is advisory only and does not bind the Company nor its directors, the Board and Remuneration Committee takes into consideration the feedback we receive from shareholders.

An explanation of the item is to be found on page 9 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please raise your hands or submit your questions via the Q&A function.

[PAUSE AND TAKE QUESTIONS]

Members of the Company's key management personnel who were named in the FY2025 remuneration report and their closely related parties are reminded that they may not vote on this resolution.

If there are no further questions I will move to the next resolution.

Resolution 2: Re-election of Director – Mr Peter Osborne

I put forward Resolution 2:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 2,** as an **ordinary resolution**.

"That Peter Osborne, a director retiring by rotation in accordance with clause 14.4 of the Constitution, being eligible and having consented to act, be re-elected as a director of the Company."

An explanation of Resolution 2 and information on Mr. Osborne is found on page 10 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please raise your hands or submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

If there are no further questions I shall move to the next resolution.

Resolution 3: Share-Buy Back

I put forward Resolution 3:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 3,** as an **ordinary resolution**.

"*That pursuant to and in accordance with section 257C of the Corporations Act 2001 (C'wlth), as amended, Rules 7.29 and 7.33 of the Listing Rules of ASX Limited, and for all other purposes, the shareholders approve, with effect from when the Directors make the relevant announcement to the ASX, the on-market buy-back of up to 15% of the fully paid ordinary shares in the Company expiring on whichever is the earlier of the anniversary of the passage of this resolution or the 2027 Annual General Meeting and otherwise on the terms and* *conditions set out in the Explanatory Statement accompanying the 2026 Annual General Notice of Meeting at which this resolution is to be put*."

An explanation of Resolution 3 and information the share buy-back, is found from page 10 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please raise your hands or submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

If there are no further questions I shall move to the next resolution.

Resolution 4: Long Term Incentive Plan: Grant of A Limited Recourse Loan to a Director to Purchase Ordinary Shares

I put forward the following motion under Resolution.

To consider and, if thought fit, to pass, with or without amendment, **Resolution 4**, as an **ordinary resolution**.

"That pursuant to ASX Listing Rules 10.14 and in accordance with Vita Life Sciences Limited's "2024 Long Term Incentive Plan" (2024 Long Term Incentive Plan), tabled by the Chairman and initialled by him for purposes of identification, approval is given for the Directors to issue 600,000 new ordinary, fully paid shares in the Company and make a limited recourse loan to Mr Andrew O'Keefe, acting in his capacity as the Director of the Company, for a sum of $1,515,000 (Loan), which will be used to fund the purchase of shares, on the terms summarised in the Explanatory Statement accompanying the Notice of 2026 Annual General Meeting.".

An explanation of Resolution 4, is found from page 13 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Ladies and gentlemen, that concludes the resolutions to be voted. As mentioned, we are conducting a Poll on all resolutions. For this purpose, I appoint Mathew Hunter of Automic Registry Services shall be the Returning Officer.

When you registered your attendance, voting shareholders and proxy holders were given a Yellow voting card. On this card you will find a series of boxes for voting. For your vote to count, you must tick or mark the corresponding “For”, “Against” or “Abstain” boxes.

As a proxyholder, when completing the voting card on the poll, you need only mark a box, if you have “discretionary” votes.

When voting is completed, staff from Automic will collect your voting cards.

I now ask that you complete your voting cards for all resolutions.

If there are any shareholders who have not handed in the voting card and if you wish to do so, kindly raise your hand.

I shall now declare voting is closed.

The staff of Automic will now collect the voting cards and process the poll. The results will be announced to the ASX once available.

If you have any questions, please raise your hands or submit your questions via the Q&A.

If there are no further questions I shall move to the next item.

AGENDA 3 OTHER BUSINESS & QUESTION TIME

Is there any other business that can lawfully be brought forward?

[PAUSE TO CONSIDER]

If there are none, I now invite shareholders to raise their hand if there are any questions for management or the auditor, or submit it via the Q&A function.

[PAUSE AND TAKE QUESTIONS]

MEETING CLOSE

There being no further questions or matters for discussion, I'd like to thank all shareholders for their attendance and will now end the today's meeting. I declare the meeting closed.

Managing Director Address – Annual General Meeting 2026

Good afternoon shareholders, colleagues, and partners.

Thank you for joining us today for the 2026 Annual General Meeting of Vita Life Sciences. It is a pleasure to welcome you, whether you are here with us in person or joining online. Your continued support and engagement are vital to our success, and I am grateful for the opportunity to share with you the progress we have made over the past year and the exciting opportunities ahead.

Opening Remarks

As we gather today, I am proud to report that Vita Life Sciences has delivered another year of strong performance, disciplined execution, and meaningful strategic advancement. The 2025 results reflect not only the resilience of our business model but also the dedication of our people and the trust of our customers across the region.

We have continued to grow, to innovate, and to strengthen our position in the markets we serve. And we have done so while maintaining the financial discipline and operational focus that have become hallmarks of our organisation.

Financial Performance

Let me begin with our financial results, which demonstrate the strength and momentum of the business.

For the 2025 financial year, the Group delivered record full-year performance, with revenue reaching $93.3 million, an increase of 17.3% on the prior corresponding period. Profit before tax rose to $14.4 million, up 14.1%, and our gross profit margin increased by 1.7% to 61%.

Our cash conversion remained exceptionally strong at 126%, and we closed the year with cash reserves of $35.6 million and equity of $56.2 million, with no bank borrowings. This is a position very few companies in our sector can claim, and it reflects our disciplined approach to capital management and our commitment to maintaining a strong, flexible balance sheet.

We also executed a $2.2 million share buyback, further demonstrating our confidence in the long-term value of the business and our commitment to delivering returns to shareholders.

VLS Financial History

Looking beyond the year in isolation, our five-year performance tells a compelling story of sustained growth and strategic progress.

Over the past five years:

- Revenue has grown by 101%.
- Pre-tax profit has grown by 70%.
- Our product portfolio has expanded significantly.
- Our market presence has deepened across the region.

Our focus on delivering sustainable value is reflected in our dividend performance. This year, the Board declared a full-year dividend of 14 cents per share, an increase of 4 cents on the prior year. This marks 16 consecutive years of dividend payments and a compound annual dividend growth rate of 24% over the past six years.

These results are not accidental. They are the outcome of a clear strategy, disciplined execution, and a commitment to long-term value creation.

Delivering Disciplined Growth

Our focus remains on delivering disciplined growth and maintaining margin resilience across the business.

- Domestic channels continue to perform well, providing a stable base for growth
- Allocating capital carefully and maintaining a strong balance sheet to support long-term value creation
- Despite competitive pressures, we've protected margins through efficiency, pricing discipline and portfolio strength
- Prioritising initiatives and segments that deliver sustainable, profitable growth
- Our business remains profitable and cash-generative, enabling reinvestment and strategic flexibility

These pillars position us to continue delivering disciplined, sustainable growth.

Operational Performance Across Markets

Our growth this year was broad based, with strong sales and profit contributions flowing through from our existing major markets in Australia, Malaysia / Singapore.

During this period the Group deployed a revised market strategy in China, including the appointment of a new exclusive distributor for Herbs of Gold across pharmacy and e-commerce channels. This is a significant step forward in a market that remains strategically important for us, and we are confident that our refined approach will position us for long-term success. The China market continues to experience an evolving regulatory environment and changing channel dynamics. The Group will maintain a measured and disciplined approach to managing these developments moving forward.

Vietnam is beginning to show encouraging green shoots following recent product listings across key pharmacy chains for both the VitaHealth and Herbs of Gold brands, supporting improved market visibility and distribution momentum.

Turning to Indonesia, our strategy has been slower than initially anticipated, the Group remains focused on ensuring the right long-term partnership and operating model to support in market activities. The market itself continues to represent a strategic opportunity for the Group and remains an active focus area for both Management and the Board.

Overall, the Group enters the new financial year with strong operational foundations, a clear strategic focus and confidence in our ability to execute across our respective markets.

Our People and Global Footprint

Our success is driven by our people over 350 employees across Australia, Malaysia, Singapore, China, Indonesia, and Vietnam. Our teams include naturopaths, nutritionists, herbalists, biotechnologists, and pharmacists, all united by a shared commitment to improving health and wellbeing.

Our products are now available in over 3,000 retailers, including some of the largest offline and online health and pharmacy partners in the region.

We are proud of our global footprint, and we remain committed to expanding our presence in a disciplined and strategic manner.

Marketing and Brand Investment

Our marketing investment increased by 23%, enabling us to connect with millions of consumers across television, digital, social, radio, outdoor, print, and in-store channels. This integrated approach ensures that our brands remain visible, relevant, and trusted.

These initiatives are not just about visibility—they are about building lasting relationships with consumers and positioning our brands as leaders in health and wellness.

Product Innovation

Innovation remains at the heart of our growth strategy. Across the business, we now have over 350 registered products, and in 2025 alone, we launched 23 new products across Australia, Malaysia, and Singapore.

These new products reflect our commitment to meeting evolving consumer needs, staying ahead of market trends, and ensuring that our portfolio remains competitive and relevant.

Awards and Industry Recognition

Our brands and teams continue to be recognised across the region.

In Australia, we were named:

- Top Ranked Supplier (Pharmacy – OTC) for 2023, 2024, and 2025
- Natural Health Supplier of the Year – Wholelife Pharmacy group.

Just to name a few.

In Malaysia, we received multiple awards, including:

- Malaysian Business of the Year – Star business awards
- Best Halal Product (Platinum)
- Multiple category awards from Guardian and Watsons

And in Singapore, we were recognised with:

- Consumers' Choice Superbrands
- Best Marketing Collaboration

These accolades reflect the hard work of our teams and the trust placed in our brands by consumers and partners.

Strategic Priorities

Moving forward our strategy remains focused and clear. Our priorities for the coming year include:

- Maintaining momentum in offshore markets
- Driving margin through product mix, pricing, and efficiency
- Disciplined capital deployment
- Pursuing accretive acquisition opportunities
- Defending and growing our profitable core channels

These priorities reflect our commitment to sustainable growth, operational excellence, and long-term value creation.

ESG and Social Responsibility

We are also committed to strengthening our Environmental, Social, and Governance (ESG) strategy. This year, we expanded our partnerships including receiving B Corp certification for the Australian business and developed programs focused on education and literacy.

These efforts reflect our belief that long-term success is built not only on financial performance, but also on the positive impact we create for our communities and the planet.

Closing Remarks

In closing, I want to express my sincere gratitude to our shareholders for your continued trust, to our partners for your collaboration, and to our employees for your dedication and passion.

Vita Life Sciences is stronger today than at any point in its history. With a resilient business model, a strong balance sheet, and a clear strategic roadmap, we are well positioned to continue delivering sustainable growth and long-term value.

Thank you for your support, and I look forward to another successful year ahead.

VITA LIFE SCIENCES

Annual General Meeting
28 May 2026

VITA LIFE SCIENCES

Managing Director- Annual General Meeting May 2026

Financial Highlights

- Record full year performance
- Gross profit margin ↑ 1.7% to 61%
- Cash conversion: strong 126%
- Strong balance sheet with no borrowings
- Share buyback: $2.2M

PBT
$14.4M
UP 14.1% VS PCP

REVENUE
$93.3M
UP 17.3% VS PCP

Full year dividend
14CPS

EQUITY
$56.2M

CASH RESERVES
$35.6M
(no borrowing)

DIVIDEND
A full year dividend of 14.0 cents per share was declared for the period, representing an increase of 4.0 cent per share on PCP.

The Group maintains a strong balance sheet with equity of $56.2 million and cash reserves of $35.6 million, with no bank borrowings.

VITA LIFE SCIENCES

VLS Financial History





- Revenue growth of 101% over last 5 years
- Pre-tax profit growth of 70% over last 5 years

- Compounded annual dividend growth of 24% over 6 years
- 16 consecutive years of dividend payments

Delivering disciplined growth and margin resilience

Strong domestic channel performance

Disciplined capital management and balance sheet strength

Margin resilience despite competitive pressures

Profitable, cash-generative healthcare business

Clear focus on profitable growth and execution

Operational highlights

Segment performance - Broad based growth across core markets, supported by strong performances across all major channels and positive consumer sentiment.

- Australia **up 8%**
- Malaysia & Singapore **up 35%**

Market initiatives

- Continued distribution expansion in Australia, Malaysia and Singapore, with targeted initiatives to strengthen market penetration.
- Revised market strategy in China deployed.
- Appointment of new exclusive distributor for Herbs of Gold across the Pharmacy and e-commerce channels.

Marketing and Brand Investment

- Advertising and promotional investment increased by 23% on PCP, driving brand visibility and consumer engagement.

Our People

OVER 350 EMPLOYEES

We have over 350 employees in the Vita Life Sciences Group across Australia, Malaysia, Singapore, China, Indonesia and Vietnam. We have teams of qualified naturopaths, nutritionists, herbalists, biotechnologists, and pharmacists. and online retailers in the health food and pharmacy sector.

Our Markets

AUSTRALIA
MALAYSIA
SINGAPORE
VIETNAM
INDONESIA
CHINA

We continue to evolve and expand our global presence.
We are currently in 6 markets.

Our Partners

GO VITA, Healthy Life, WHOLELIFE, TerryWhite Chemmart, Amcal+, priceline, Blooms THE CHEMIST, HEALTH LANE, Discount Drug Stores, GrabMart, pharmacy alliance, WIZARD pharmacy, NUTRITION WAREHOUSE, Wellness, LiveLife PHARMACY, CARING PHARMACY, guardian, National Pharmacies, Lazada, SUNWAY Multicare Pharmacy, AA pharmacy, BIG PHARMACY, Chemsave

OVER 3000 RETAILERS

Our products are available across some of the biggest offline and online retailers in the health food and pharmacy sector.

Marketing

Our marketing investment combines global scale with a deep understanding of local audiences. We connect with millions of consumers through coordinated activity across television, digital, social, radio, outdoor, print, and in-store channels. By integrating these platforms, we ensure our campaigns are relevant, consistent, and accessible, strengthening engagement and building lasting connections with diverse communities.

Brand Positioning

VitaHealth

VitaHealth has been a people-focussed and trusted brand for over 50 years. We continue to position VitaHealth as the brand that genuinely cares. 2024 pushed this positioning further by delivering 9 major marketing and community events, as well as, entering into 4 new corporate partnerships.

NPD 2025

There are currently over **350 products** registered across the business.

23 new products
launched across Australia, Malaysia and Singapore.

Australia

TOP RANKED SUPPLIER (PHARMACY – OTC) – VOICE OF THE CUSTOMER ADVANTAGE REPORT 2023, 2024 & 2025

NATURAL HEALTH SUPPLIER OF THE YEAR – WHOLELIFE PHARMACY & HEALTHFOODS

TOP GROWTH PERFORMER – CHEMIST OUTLET AWARDS

Malaysia

MALAYSIAN BUSINESS OF THE YEAR – THE STAR OUTSTANDING BUSINESS AWARDS (SOBA)

BEST HALAL PRODUCT (PLATINUM) - THE STAR OUTSTANDING BUSINESS AWARDS (SOBA)

BEST IN CSR (SILVER) - THE STAR OUTSTANDING BUSINESS AWARDS (SOBA)

BEST SELLER AWARD IN SKIN HEALTH FOR SKINTRU - GUARDIAN

MOST WANTED EFFERVESCENT FORMAT MAGNESIUM FOR V-STYLE MAGNESIUM 300MG – WATSONS

MOST WANTED SKIN BRIGHTENING SUPPLEMENT FOR L-GLUTATHIONE PLUS – WATSONS

STAR BRAND AWARDS FOR V-STYLE – WATSONS

TOP CHOICE FOR VITAMIN K2 D3 FOR VITAMINS K2+D3 – MULTICARE

Singapore

CONSUMERS' CHOICE

SUPERBRANDS

TOP SELLER, TURMERIC- SUPPLEMENTS UNITY POPULAR CHOICE AWARDS

BEST MARKETING COLLABORATION – GUARDIAN

BEST SELLER AWARD IN INNER RADIANCE FOR L-GLUTATHIONE PLUS – GUARDIAN

BEST EXCLUSIVE NMN – WATSONS

Strategic priorities

- Defend and grow profitable core channels
- Drive margin through product mix, pricing and efficiency
- Maintain momentum in offshore markets
- Disciplined capital deployment
- Accretive acquisition opportunities

Social impact & corporate responsibility

At Vita Life Sciences, we are dedicated to enhancing our Environmental, Social and Governance (ESG) strategy by embedding initiatives into our business operations to uphold the high standards we set for ourselves and our partners. We have developed partnerships with charities, launched team initiatives and are building programs to enhance education and literacy to further improve on this. These efforts reflect our commitment to making a positive impact on our communities. Our goal is to drive sustainable growth and create long-term strategies that benefit both our business and the planet.

Australian Kookaburra Kids Foundation

CUCI MALAYSIA

TROPICANA FOUNDATION

Love & Compassion for the World

National Cancer Society Malaysia
Giving Hope Celebrating Life

Malaysian Mental Health Association
MMHA

VITA LIFE SCIENCES

Thank you

RESOLUTIONS

1. Remuneration Report
2. Re-election of Director – Mr Peter Osborne
3. Share buy back
4. Long Term Incentive Plan

PROXY-RESOLUTION 1

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
1	**Adoption of the Remuneration Report**	10,403,706	41,963	15,948,484	10,217,697

PROXY-RESOLUTION 2

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
2	**Re-election of Director** (Peter Osborne)	20,663,030	-	15,948.484	336

PROXY-RESOLUTION 3

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
3	**Share buy-back**	20,643,278	928	15,948,484	19,160

PROXY-RESOLUTION 4

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
4	**Long Term Incentive Plan: Grant of a limited recourse loan to a Director to purchase ordinary shares**	19,912,899	29,255	15,948,484	721,212

DISCLAIMER

DISCLAIMER

This document has been prepared by Vita Life Sciences Limited (**Vita Life Sciences or VLS**) and comprises written material/slides for a presentation concerning Vita Life Sciences.

The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Vita Life Sciences that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct, Except for any statutory liability which cannot be excluded, Vita Life Sciences and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Vita Life Sciences disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Vita Life Sciences since the date of this presentation.

VITA LIFE
SCIENCES

Thank you